Pioneering Treatment for Rectal Cancer Shows Promise in Avoiding Surgery

A study by Uppsala University reveals that a novel treatment for locally advanced rectal cancer can double the chance of avoiding surgery and preserving normal rectal function. This approach, involving initial radiotherapy and chemotherapy, significantly reduces tumor recurrence and the likelihood of metastases.

Positive outcomes from a novel treatment for locally advanced rectal cancer include the potential complete avoidance of surgery and a decreased chance of recurrence, according to a comprehensive study by Uppsala University published in eClinicalMedicine.

"The tumor often disappears completely, increasing the likelihood of avoiding surgery and maintaining normal rectal function. Additionally, there are fewer instances of metastases," stated Bengt Glimelius, Professor of Oncology at Uppsala University and Senior Consultant at Uppsala University Hospital. Rectal cancer impacts approximately 2,000 individuals in Sweden annually, a third of whom are at a high risk of recurrence. Typically, the treatment involves removing a part of the bowel, often necessitating a stoma.

The study reveals that providing all radiotherapy and chemotherapy upfront can double the chances of avoiding surgery. "If the tumor vanishes during treatment, surgery is not needed, preserving the rectum and eliminating the need for a stoma," said Glimelius. Involving data from 461 patients via the Swedish Colorectal Cancer Registry, the research confirms that the modern protocol results in fewer local recurrences than previous methods.

The study supports findings from a four-year-old randomized trial and showcases that the innovative treatment approach is valid even in everyday healthcare settings. "The traditional method failed to find any tumors in 14% of patients post-surgery, whereas the new approach doubled this success rate to 28% without an increase in local recurrence rates after nearly five years," Glimelius added.